IMVTImmunovant, Inc.

Healthcare
$30.48+106% 1Y

The financials

Immunovant, Inc. by the numbers

The next results filing is expected around Nov 9, 2026, the same week as a year ago.

Immunovant, Inc. income statement, Q1 2027 against the same quarter a year earlier
Income statementQ1 2027Q1 2026Change
Net income−$153M−$121Mn/a
Diluted EPS−$0.75−$0.71n/a

Biotechnology

Ranks #123 of 196 by RyuScore

Compare peers
PTGX+2.7%
Protagonist Therapeutics, Inc.
PCVX+9.7%
Vaxcyte, Inc.
SYRE+7.2%
Spyre Therapeutics, Inc.
IBRX+6.0%
ImmunityBio, Inc.
TGTX+3.8%
TG Therapeutics, Inc.
RYTM+1.3%
Rhythm Pharmaceuticals, Inc.